{"DataElement":{"publicId":"5041878","version":"1","preferredName":"Human Papillomavirus Vaccine Indicator","preferredDefinition":"Indicator to signify the use of a vaccine for HPV (Human Papillomavirus)","longName":"3007463v1.0:5041677v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3007463","version":"1","preferredName":"Person Human Papillomavirus Vaccine Use","preferredDefinition":"Person; a human being._Any of various papillomaviruses that infect the skin and mucous membranes of humans.sometimes progress to malignancy._Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"HPV_VACCINE_USE","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3007461","version":"1","preferredName":"Human Papillomavirus Vaccine Use","preferredDefinition":"Any of various papillomaviruses that infect the skin and mucous membranes of humans.sometimes progress to malignancy.:Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.:Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"C14226:C923:C25340","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Papillomavirus","conceptCode":"C14226","definition":"A strain of papillomavirus that can infect the skin and mucous membranes of humans.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EF67B96-7F94-5FC0-E040-BB89AD4315D2","latestVersionIndicator":"Yes","beginDate":"2010-02-06","endDate":null,"createdBy":"PANH","dateCreated":"2010-02-06","modifiedBy":"ONEDATA","dateModified":"2010-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EF67B96-7FA5-5FC0-E040-BB89AD4315D2","latestVersionIndicator":"Yes","beginDate":"2010-02-06","endDate":null,"createdBy":"PANH","dateCreated":"2010-02-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from caBIG to PhenX for PANH by script 2015-12-21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5041677","version":"1","preferredName":"Human Papillomavirus Vaccine Indicator","preferredDefinition":"Indicator to signify the use of a vaccine for HPV (Human Papillomavirus)","longName":"5041677v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not sure which one","valueDescription":"Uncertain","ValueMeaning":{"publicId":"2749725","version":"1","preferredName":"Uncertain","longName":"2749725v1.00","preferredDefinition":"Not established beyond doubt; still undecided or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uncertain","conceptCode":"C47944","definition":"Not established beyond doubt; still undecided or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D3ED582-F0E6-7509-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-05-15","modifiedBy":"MMADDINENI","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235704FF-E055-CCC5-E050-BB89AD4322CD","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235704FF-E060-CCC5-E050-BB89AD4322CD","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Cervarix","valueDescription":"Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine","ValueMeaning":{"publicId":"5041679","version":"1","preferredName":"Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine","longName":"5041679","preferredDefinition":"A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Human Papillomavirus Bivalent Vaccine","conceptCode":"C48395","definition":"A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"235704FF-E06E-CCC5-E050-BB89AD4322CD","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235704FF-E087-CCC5-E050-BB89AD4322CD","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Gardasil","valueDescription":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","ValueMeaning":{"publicId":"3944880","version":"1","preferredName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","longName":"3944880","preferredDefinition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","conceptCode":"C61087","definition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F124-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235704FF-E09B-CCC5-E050-BB89AD4322CD","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3587204","version":"1","preferredName":"Human Papillomavirus Vaccine Indicator","preferredDefinition":"Any of various papillomaviruses that infect the skin and mucous membranes of humans.sometimes progress to malignancy.:Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C14226:C923:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Papillomavirus","conceptCode":"C14226","definition":"A strain of papillomavirus that can infect the skin and mucous membranes of humans.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C910ACF8-C232-83CD-E040-BB89AD43316A","latestVersionIndicator":"Yes","beginDate":"2012-09-06","endDate":null,"createdBy":"RODGERSC","dateCreated":"2012-09-06","modifiedBy":"ONEDATA","dateModified":"2012-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"235704FF-E036-CCC5-E050-BB89AD4322CD","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-10-30","modifiedBy":"HARTLEYG","dateModified":"2016-02-09","changeDescription":"created for UAMS 10/30/15 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Have you ever received an HPV","type":"Preferred Question Text","description":"Have you ever received an HPV prophylactic vaccine Gardasil (available since 2006) or Cervarix (2009) or Garasil 9 (2014)?","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23903005-25BB-D0F9-E050-BB89AD437FEC","latestVersionIndicator":"Yes","beginDate":"2015-11-02","endDate":null,"createdBy":"RODGERSC","dateCreated":"2015-11-02","modifiedBy":"RODGERSC","dateModified":"2015-11-02","changeDescription":"created for UAMS 11/2/15 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}